Navigation Links
Rudd Report Highlights AMDL, Inc.'s Latest Business Achievements; Supports 2008 Financial Guidance
Date:8/4/2008

TUSTIN, Calif., Aug. 4 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, announced today that industry analyst Lauren Rudd has posted a second quarter FY2008 corporate update for AMDL, Inc. The full report is available http://www.RuddReport.com and includes a 12 month target price of $23 and Buy Recommendation.

Highlighted within the report are details of AMDL's recent clearance to market by the US FDA for its DR-70(R) blood test for monitoring colorectal cancer, AMDL's FY2008 financial guidance and the Company's top strategic objectives for 2008 and 2009:

-- AMDL's market strategy and distribution plans for DR-70(R), include securing SFDA approval to allow sales and distribution throughout China;

-- The Company's marketing strategy for the MYHPV(R) human papilloma virus Chip Kit;

-- Business expansion details for Jade Pharmaceutical Inc. for FY2008 including growth via new distribution channels and JPGreen Clinics;

-- AMDL's partnership strategy for the Combination Immunogene Therapy (CIT) technology;

-- AMDL's strategic plans for licensing North American drugs for manufacture and sales in China and Asia; and,

-- The Company's goals to secure SFDA approval for new products which will enable AMDL to market and distribute those products throughout China.

This newest Rudd Report also covers a Peer Group Comparison & Valuation Analysis along with views and opinions on AMDL's financial performance for FY2008. Opinions to note include the valuation for DR-70(R) which Mr. Rudd expects to reach approximately $4 million in gross profits during the second half of FY2008 with approximately $3 million in net profits and $0.20 per share in FY2008; and, comments approximating AMDL's net earnings to reach $15.2 million or about $1.01 per share.

According to Mr. Rudd, "AMDL has inherent potential to dramatically increase revenues and profitability in both the United States and China and we believe the Company is one of the most under priced stocks that we've seen in a long time."

The report does not explicitly review AMDL's second quarter 2008 results and the purpose of the interim report is to highlight key business successes that should have already impacted AMDL's share price. A follow-up report will be published once AMDL announced Q2 2008 earnings.

About AMDL: Headquartered in Tustin, CA along with its subsidiary Jade Pharmaceutical Inc. (JPI) with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 320 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(M) (206) 310-5323

(O) (206) 201-3286


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
2. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
3. CV Therapeutics Reports 2008 Second Quarter Financial Results
4. Gentiva Reports Strong Second Quarter led by Home Health Segment
5. United Therapeutics Reports Second Quarter 2008 Financial Results
6. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
7. Neurocrine Biosciences Reports Second Quarter 2008 Results
8. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
9. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
(Date:2/23/2017)... CARDIFF, UK (PRWEB) , ... February 22, 2017 ... ... for optics and photonics , have been named Fellows of the Society this ... and technical contributions in the multidisciplinary fields of optics, photonics, and imaging as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
(Date:2/22/2017)... Washington, PA (PRWEB) , ... ... ... Omnia-Prova Education Collaborative (TOPEC), the leading medical education provider of women’s ... with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). ACCME’s ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
Breaking Biology News(10 mins):